EXAI News and Press, Exscientia Limited From 11/18/21

Exscientia plc (EXAI) Q3 2021 Earnings Conference Call November 18, 2021 08:30 ET Company Participants Sara Sherman - Vice President, Investor Relations Andrew Hopkins - Chief Executive Officer Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Off...

Exscientia (NASDAQ:EXAI): Q3 GAAP EPS of -£0.06. Revenue of £17.6M (+1660.0% Y/Y) Press Release For further details see: Exscientia reports Q3 results

Exscientia (Nasdaq: EXAI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117006300/en/ (Graphic: Business Wire) Recent advancements in the Company’s pipeline, collaborations and operations as we...

Company to host conference call and webcast on November 18, 2021 at 1:30 p.m. GMT / 8:30 a.m. ET Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, wi...

Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-fr...

Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United State...